RYAH RYAH Group Inc

RYAH Group, Inc. Enters New Zealand Market, signs Distribution Agreement with Medical Kiwi Ltd

NEW YORK, May 10, 2021 (New York, NY) -- InvestorsHub NewsWire -- RYAH Group, Inc's (CSE:RYAH) wholly owned subsidiary, RYAH Medtech, Inc., a medical device, data and technology company announced today that it has entered into a definitive wholesale supply and distribution agreement with Medical Kiwi Ltd: a leader in R&D, manufacturing, cultivation and distribution of medical cannabis and medical devices. The newly formed cooperation implies distribution of the RYAH Smart Inhaler and cloud based data analytics platform in New Zealand. The agreement was executed on April 5, 2021

The new agreement will enable RYAH's suite of connected IoT devices and cloud-based data analytics to be connected with Medical Kiwi's cultivated medical cannabis formulations and patient network for pre-clinical and clinical trial settings as well as medical patient care in New Zealand.

In addition, RYAH and Medical Kiwi intend to explore medical device registration for the RYAH dose-control Smart-Inhaler, which would be the first of its kind in the country.

"Our new partnership with Medical Kiwi Ltd in New Zealand further expands our global  clinical and distribution network for plant-based medicine and digital patient care,." said Gregory Wagner, CEO of RYAH Group Inc. and of RYAH Medtech, Inc. "In December 2019, the New Zealand Government passed legislation to improve access to medical cannabis products. Our new relationship with Medical Kiwi presents an opportunity for both parties to drive innovation and to deliver cutting edge plant-based medical solutions in New Zealand. " – Gregory Wagner, CEO of RYAH Medtech, Inc.

About Medical Kiwi Ltd

Medical Kiwi Ltd is a medical cannabis market leader in New Zealand that has built a strong health-based, scientific and business savvy team, developed a clear plan for research, product development and distribution and successfully raised our initial seed fund capital and crowdfunding equity. With signing partnership agreements with global industry-leading companies, Medical Kiwi has been granted a Medicinal Cannabis licence from the Ministry of Health to cultivate, manufacture and supply medicinal cannabis.

About RYAH Group, Inc.

RYAH Group, Inc. ('RYAH') is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and Licensed Processors (LPs) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle.

Forward-Looking Statements

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the benefits of RYAH's user-generated, HIPAA-compliant data; the success of its launch in Europe; RYAH's plan to roll-out several other clinical delivery mechanisms; the results users may receive from using RYAH products; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; legal and regulatory risks inherent in the cannabis industry; risks relating to the regulatory landscape in certain countries and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to proprietary intellectual property and potential infringement by third parties; risks inherent in an agricultural business; risks associated to cannabis products manufactured for human consumption including potential product recalls; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

RYAH Medtech Inc Contacts:

Gregory Wagner, CEO

invest@ryah.com

917 210 0543

Sofiya Kleshchuk

Client Relations

+1 917 210 0543

Public Relations:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

RYAH (CSE:RYAH)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

RYAH (CSE:RYAH)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024